Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Pharma Inc.

www.astellas.com

Latest From Astellas Pharma Inc.

Scotland’s SMC OKs Drugs For Cancer & Plaque Psoriasis

The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.

United Kingdom Health Technology Assessment

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting

International Innovation

Apotex Suffers Adverse Tarceva Reversal

Apotex has seen last years decision that a patent protecting the Tarceva erlotinib oncology brand until 2021 was obvious overturned by a US Court of Appeals.

Intellectual Property Cancer

Can Novartis Reclaim Pioneering Role In Transplantation?

Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.

Clinical Trials Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register